Saturday, October 31, 2026

Inovio Pharmaceuticals Stock Is 16% Down In The Last 5 Sessions

Inovio Pharmaceuticals Stock Is 16% Down In The Last 5 Sessions

Shares of biotechnology company Inovio Pharmaceuticals (NASDAQ: INO) have recently been on a sharp decline. Over the course of five consecutive sessions, the company's stock plummeted by more than 16%, dropping to sh.42. This drop contributed significantly to NATDAQ's overall decrease of 1.12%. As of now, Inovio Pharmaceuticals' shares are trading at prices 84.93% lower than their 52-week high of .82. This marks the company's worst performance in its history.

Inovio's Services

Despite these setbacks in the stock market, Inovio Pharmaceuticals continues to stand out in the biotechnology industry. The company is highly dedicated to discovering, developing, and commercializing DNA medicines. The primary intent behind these medicines is to treat and prevent conditions such as human papillomavirus (HPV), cancer, and other infectious diseases.

Financial Difficulty

Although Inovio Pharmaceuticals has made significant contributions to medical research, it continues to struggle financially. While the company's earnings per share (EPS) over the trailing twelve months was somewhat satisfactory at 1.01, its efforts in R&D did not lead to an increase in return on equity (ROE). During the same period, the company's ROE hit a concerning low of negative 87.1%.

Furthermore, Inovio's quarterly revenue has been less than ideal. Over the last twelve months, its growth decreased by a massive 42.3%, leaving the total revenue for the trailing twelve months at a mere $10M.

Inovio's Stock Performance

When observing Inovio Pharmaceuticals' 52-week high and low stock values, it is evident that the company is in a downward spiral. Currently, its stock is trading below its 52-week high of sh.644, although it is slightly above its 52-week low of sh.385. This decline is further highlighted by the company's stock falling significantly below both its 50-day moving average of sh.54 and its 200-day moving average of .244.

The Future of Inovio

All these factors underline the pressing need for Inovio Pharmaceuticals to take strategic measures to boost profitability and restore the trust of its investors. The company's current situation also underlines the importance of financial literacy. Understanding how a company's performance within an industry influences stock market profitability is an invaluable asset for any investor.

More news about Inovio Pharmaceuticals (INO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com